CIZZLE BIOTECHNOLOGY HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.675 GBX | 0.00% |
|
-1.47% | -14.10% |
| Apr. 30 | EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down | AN |
| Apr. 30 | Cizzle Biotechnology Holdings Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 7.09M 9.01M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 | -1M -1.27M | EV / Sales 2022 | - |
| Net cash position 2022 | 478K 607K | Net cash position 2023 | 1.56M 1.98M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.63
x | P/E ratio 2023 |
-4.04
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.98% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -1.47% | ||
| Current month | +1.52% | ||
| 1 month | -4.29% | ||
| 3 months | -27.17% | ||
| 6 months | -11.84% | ||
| Current year | -14.10% |
1 week
1.60
1.85
1 month
1.571.85
Current year
1.573.38
1 year
1.573.38
3 years
1.308.25
5 years
1.3013.00
10 years
1.3013.00
| Managers | Title | Age | Since |
|---|---|---|---|
Nigel Lee
DFI | Director of Finance/CFO | 63 | 21-05-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dawn Coverley
BRD | Director/Board Member | 59 | 21-05-13 |
Nigel Lee
DFI | Director of Finance/CFO | 63 | 21-05-13 |
John Treacy
BRD | Director/Board Member | 42 | 19-01-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 1.675 | 0.00% | 473,742 |
| 24-05-16 | 1.675 | 0.00% | 237,217 |
| 24-05-15 | 1.675 | -5.63% | 1,553,414 |
| 24-05-14 | 1.775 | 0.00% | 415,414 |
| 24-05-13 | 1.775 | +4.41% | 1,513,628 |
Delayed Quote London S.E., May 17, 2024 at 11:35 am EDT
More quotes
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.10% | 8.44M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- PSL Stock
